Characterization of the antigens in inactivated porcine circovirus type 2 vaccines and virus-like particle vaccines by high-performance size-exclusion chromatography coupled with multi-angle laser light scattering.

Yuan XU; Yanli Yang; Xingqi Zou; Cui LI; Yuanyuan Zhu; Yixian Qin; Yan LI; Ya Nan Sheng; Yebing Liu; Guorui Peng; Xiaoai XU; Songping Zhang; Qizu Zhao

Return

Characterization of the antigens in inactivated porcine circovirus type 2 vaccines and virus-like particle vaccines by high-performance size-exclusion chromatography coupled with multi-angle laser light scattering.

Author: Yuan XU ¹ ; Yanli YANG ² ; Xingqi ZOU ¹ ; Cui LI ¹ ; Yuanyuan ZHU ¹ ; Yixian QIN ¹ ; Yan LI ¹ ; Ya Nan SHENG ² ; Yebing LIU ¹ ; Guorui PENG ¹ ; Xiaoai XU ¹ ; Songping ZHANG ² ; Qizu ZHAO ¹
Author Information

1. China Institute of Veterinary Drug Control, Beijing 100081, China.
2. State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
Publication Type:Journal Article
Keywords: Cap; high-performance size-exclusion chromatography (HPSEC); multi-angle laser light scattering (MALLS); porcine circovirus type 2 (PCV2); vaccine; virus-like particles (VLP)
MeSH: Animals; Antibodies, Viral; Capsid Proteins; Chromatography, Gel; Circoviridae Infections/prevention & control*; Circovirus; Lasers; Swine; Vaccines, Inactivated; Vaccines, Virus-Like Particle; Viral Vaccines
From: Chinese Journal of Biotechnology 2022;38(8):2948-2958
CountryChina
Language:Chinese
Abstract: This paper aims to detect the antigens in porcine circovirus type 2 (PCV2) vaccines by high-performance size-exclusion chromatography (HPSEC) coupled with multi-angle laser light scattering (MALLS). With purified inactivated PCV2 and PCV2 virus-like particles (VLP) as references, two inactivated vaccines (a and b) and two VLP vaccines (c and d) for PCV2 from four manufacturers were analyzed by HPSEC-MALLS after demulsification. The antigen peaks in HPSEC-MALLS were identified by PCV2 antigen test strips, Western blotting and transmission electron microscope (TEM). The repeatability and linearity of the method were investigated. The results showed the virus antigens in the two inactivated vaccines were eluted at about 13.3 min in HPSEC. The molecular weight of these antigens was 2.61×10⁶ (±4.34%) Da and 2.40×10⁶ (±2.51%) Da, respectively, as calculated by MALLS. The antigen peaks of the two VLP vaccines also appeared at 13.3 min and the molecular weight was 2.09×10⁶ (±2.94%) Da and 2.88×10⁶ (±11.85%) Da, respectively, which was close to the theoretical molecular weight of PCV2. Moreover, an antigen peak of VLP vaccine c was observed at 11.4 min and the molecular weight was 4.37×10⁶ (±0.42%) Da. The antigen was verified to be the dimer of VLP by TEM. Vaccine d and purified Cap VLP antigens were tested repeatedly, and the RSD of the peak area (n=3) was all < 1.5%, indicating that the method was repeatable. The purified VLP were diluted in serial and tested for linearity. The result suggested good linear relationship between the peak area of VLP or VLP aggregates and the protein concentration of the sample with R² of 0.999 and 0.997, respectively. Thus, the method met the requirement for quantification and aggregate analysis. This method is accurate and efficient in in vitro quality evaluation and improvement of PCV2 vaccine.